Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Federal regulation: philosophy and practice.

C N Christensen

    Annals of Internal Medicine
    |November 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Government drug regulation ensures safety and efficacy but has increased costs and slowed new drug approvals. This analysis questions if the benefits of centralized control outweigh these significant expenses.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The position of the pharmaceutical industry in the development of drugs for pediatric use.

    Pediatric pharmacology (New York, N.Y.)·1980
    Same author

    Panel on pediatric trials.

    Clinical pharmacology and therapeutics·1975
    Same author

    [IMMUNIZATION AGAINST MEASLES].

    Jornal de pediatria·1964
    Same author

    A FIELD TRIAL OF AN INACTIVATED MEASLES VIRUS VACCINE.

    Southern medical journal·1963
    Same author

    More risky to give, or not to give?

    American journal of diseases of children (1960)·1963
    Same author

    Reactions to poliomyelitis vaccine.

    Journal of the American Medical Association·1959
    Same journal

    Correction to I.M. Matters News: Sleep medicine for seniors.

    Annals of internal medicine·2026
    Same journal

    Adverse Events After Same-Day COVID-19 and Influenza Vaccination Versus Influenza Vaccination Alone : A Target Trial Emulation.

    Annals of internal medicine·2026
    Same journal

    Leveraging Real-World Evidence to Inform Regulatory, Clinical, and Coverage Decisions Related to Glucagon-Like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Methodological Approaches to Real-World Evidence Generation for Glucagon-like Peptide-1-Based Therapies: Synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

    Annals of internal medicine·2026
    Same journal

    Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.

    Annals of internal medicine·2026
    Same journal

    Grappling with GLP-1 prescribing.

    Annals of internal medicine·2026
    See all related articles

    Area of Science:

    • Pharmacology and Toxicology
    • Health Policy and Law
    • Drug Development and Regulation

    Background:

    • Congressional philosophy on drug regulation has evolved to include misbranding, adulteration, safety, efficacy, and investigational processes.
    • Regulations aim to protect public health by ensuring drug safety and effectiveness.
    • This has led to increased government control, impacting drug development timelines and costs.

    Purpose of the Study:

    • To evaluate the evolving landscape of drug regulation in the United States.
    • To analyze the impact of centralized government control on drug development and approval processes.
    • To assess the cost-benefit ratio of current drug regulatory practices.

    Main Methods:

    • Review of legislative intent and regulatory frameworks governing drug approval.

    Related Experiment Videos

  • Analysis of trends in new drug development and approval timelines.
  • Examination of the economic impact of regulatory compliance on the pharmaceutical industry.

    • Main Results:

    • Centralized drug regulation has led to a slowdown in new drug approvals.
    • The cost of developing and marketing new drugs has significantly increased.
    • Regulatory control procedures have become more expensive and complex.

    Conclusions:

    • While aiming to ensure safety and efficacy, current drug regulatory systems may impose excessive costs and delays.
    • A re-evaluation of the balance between public health protection and regulatory efficiency is warranted.
    • The benefits of centralized government control in drug regulation may be outweighed by its economic and developmental costs.